NCT05737628
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05737628
Title First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Byondis B.V.
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | ITA | GBR | ESP

Facility Status City State Zip Country Details
ASST Spedali Civili di Brescia Brescia Italy Details
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo Italy Details
Instituto Europeo di Oncologia Milan Italy Details
IRCCS Ospedale San Raffaele Milan Italy Details
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS IRST Ravenna Italy Details
Vrije Universiteit Medisch Centrum Amsterdam Netherlands Details
Radboud UMC Nijmegen Netherlands Details
Hospital Universitari Vall d'Hebron Barcelona Spain Details
Institut Català d'Oncologia Barcelona Spain Details
Centro Integral Oncológico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro Madrid Spain Details
The Christie NHS Foundation Trust Manchester United Kingdom Details
University Hospitals Plymouth NHS Trust Plymouth United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field